{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:53:54Z","timestamp":1790654034260,"version":"4.1.0"},"reference-count":128,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Breast cancer is a prevalent disease that has a substantial impact on women\u2019s mortality rates. Shikonin, a naphthoquinone derived from Lithospermum erythrorhizon, has demonstrated substantial anticancer effects. This study aims to conduct a comprehensive review of the latest research findings regarding the therapeutic efficacy of shikonin in the context of breast cancer treatment, with a specific emphasis on elucidating the underlying molecular mechanisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A comprehensive literature review was conducted on shikonin and breast cancer by searching PubMed, Scopus, Web of Science, and Google Scholar databases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Shikonin significantly reduces tumor cell viability, proliferation, migration, invasion, and metastasis in both in vivo and in vitro across all breast cancer subtypes. Additionally, when combined with other pharmaceutical agents, it exhibits synergistic effects. Shikonin stimulates immunogenic cell death, resulting in apoptosis and necroptosis. The induction of immunogenic cell death by shikonin enhances the immunogenicity of breast cancer cells, leading to its involvement in the development of dendritic cell-based tumor vaccines against breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Shikonin exhibits potent anti-breast cancer properties and shows significant potential for the advancement of immunotherapeutic approaches against breast cancer, as well as enhancing the efficacy of conventional treatment strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgae041","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:57:44Z","timestamp":1713880664000},"page":"967-982","source":"Crossref","is-referenced-by-count":23,"title":["Shikonin in breast cancer treatment: a comprehensive review of molecular pathways and innovative strategies"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-1554","authenticated-orcid":false,"given":"Saeid","family":"Iranzadeh","sequence":"first","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Shahed University , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Dalil","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Shahed University , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Kohansal","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Shahed University , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Isakhani","sequence":"additional","affiliation":[{"name":"Student Research Committee, Faculty of Medicine, Shahed University , Tehran ,","place":["Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"2024110501461482600_CIT0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume-title":"CA Cancer J Clin","author":"Sung","year":"2021"},{"key":"2024110501461482600_CIT0002","first-page":"524","article-title":"Breast cancer statistics, 2022","volume-title":"CA Cancer J Clin","author":"Giaquinto","year":"2022"},{"key":"2024110501461482600_CIT0003","first-page":"619","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume-title":"Cancer Epidemiol Biomarkers Prev","author":"Howlader","year":"2018"},{"key":"2024110501461482600_CIT0004","first-page":"12","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists","volume-title":"J Breast Imaging","author":"Johnson","year":"2021"},{"key":"2024110501461482600_CIT0005","first-page":"3131","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume-title":"J Cancer","author":"Dai","year":"2017"},{"key":"2024110501461482600_CIT0006","first-page":"409","article-title":"Luminal breast cancer: risk of recurrence and tumor-associated immune suppression","volume-title":"Mol Diagn Ther","author":"Pellegrino","year":"2021"},{"key":"2024110501461482600_CIT0007","first-page":"125","article-title":"Personalizing breast cancer staging by the inclusion of ER, PR, and HER2","volume-title":"JAMA Surg","author":"Bagaria","year":"2014"},{"key":"2024110501461482600_CIT0008","first-page":"632357","article-title":"Meta-analysis of HER2-enriched subtype predicting the pathological complete response within HER2-positive breast cancer in patients who received neoadjuvant treatment","volume-title":"Front Oncol","author":"Shen","year":"2021"},{"key":"2024110501461482600_CIT0009","doi-asserted-by":"crossref","first-page":"681476","DOI":"10.3389\/fonc.2021.681476","article-title":"Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer","volume":"11","author":"Ensenyat-Mendez","year":"2021","journal-title":"Front Oncol"},{"key":"2024110501461482600_CIT0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2478\/v10019-010-0054-4","article-title":"Triple negative breast cancer-prognostic factors and survival","volume":"45","author":"Ovcaricek","year":"2011","journal-title":"Radiol Oncol"},{"key":"2024110501461482600_CIT0011","doi-asserted-by":"crossref","first-page":"599073","DOI":"10.3389\/fonc.2020.599073","article-title":"Chinese herbal medicine for reducing chemotherapy-associated side-effects in breast cancer patients: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"2024110501461482600_CIT0012","doi-asserted-by":"crossref","first-page":"102793","DOI":"10.1016\/j.amsu.2021.102793","article-title":"Breast cancer resistance to chemotherapy: when should we suspect it and how can we prevent it","volume":"70","author":"Faruk","year":"2021","journal-title":"Ann Med Surg"},{"key":"2024110501461482600_CIT0013","first-page":"241","article-title":"Circular RNAs in breast cancer diagnosis, treatment and prognosis","volume-title":"Oncol Res","author":"Huang","year":"2023"},{"key":"2024110501461482600_CIT0014","first-page":"0098","article-title":"Novel combination therapy for triple-negative breast cancer based on an intelligent hollow carbon sphere","volume-title":"Research (Washington, D.C.)","author":"Yin","year":"2023"},{"key":"2024110501461482600_CIT0015","first-page":"105","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume-title":"Mol Cancer","author":"Ye","year":"2023"},{"key":"2024110501461482600_CIT0016","first-page":"750","article-title":"Molecular aspects and therapeutic implications of herbal compounds targeting different types of cancer","volume-title":"Molecules","author":"Sharma","year":"2023"},{"key":"2024110501461482600_CIT0017","first-page":"979634","article-title":"Anticancer potential of cryptotanshinone on breast cancer treatment; a narrative review","volume-title":"Front Pharmacol","author":"Dalil","year":"2022"},{"key":"2024110501461482600_CIT0018","first-page":"2165","article-title":"Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint","volume-title":"Molecules","author":"Islam","year":"2022"},{"key":"2024110501461482600_CIT0019","first-page":"781850","article-title":"Evidence and potential mechanism of action of Lithospermum erythrorhizon and its active components for psoriasis","volume-title":"Front Pharmacol","author":"Wang","year":"2022"},{"key":"2024110501461482600_CIT0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ptr.1100","article-title":"Cellular pharmacology studies of shikonin derivatives","volume":"16","author":"Chen","year":"2002","journal-title":"Phytother Res"},{"key":"2024110501461482600_CIT0021","first-page":"107558","article-title":"Antibiofilm activity of shikonin against Listeria monocytogenes and inhibition of key virulence factors","volume-title":"Food Control","author":"Li","year":"2021"},{"key":"2024110501461482600_CIT0022","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1248\/bpb.34.197","article-title":"Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro","volume":"34","author":"Gao","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"2024110501461482600_CIT0023","doi-asserted-by":"crossref","first-page":"e10675","DOI":"10.17433\/978-3-17-040947-7","article-title":"Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis","volume-title":"PeerJ","author":"Han","year":"2021"},{"key":"2024110501461482600_CIT0024","doi-asserted-by":"crossref","first-page":"108747","DOI":"10.1016\/j.cbi.2019.108747","article-title":"Application of \u201cmacromolecular crowding\u201d in vitro to investigate the naphthoquinones shikonin, naphthazarin and related analogues for the treatment of dermal scars","volume":"310","author":"Fan","year":"2019","journal-title":"Chem Biol Interact"},{"key":"2024110501461482600_CIT0025","first-page":"131","article-title":"Lithospermum erythrorhizon cell cultures: present and future aspects","volume-title":"Plant Biotechnol","author":"Yazaki","year":"2017"},{"key":"2024110501461482600_CIT0026","first-page":"1453","article-title":"Antitumor effect and mechanism of shikonin derivative SYUNZ-7","volume":"24","author":"Huang","year":"2005","journal-title":"Ai zheng= Aizheng= Chin J Cancer"},{"key":"2024110501461482600_CIT0027","first-page":"2892","article-title":"Traditional Chinese medicine remedy to jury: the pharmacological basis for the use of shikonin as an anticancer therapy","volume-title":"Curr Med Chem","author":"Andujar","year":"2013"},{"key":"2024110501461482600_CIT0028","first-page":"154608","article-title":"Phytochemicals and mitochondria: Therapeutic allies against gastric cancer","volume-title":"Phytomedicine","author":"Zhao","year":"2022"},{"key":"2024110501461482600_CIT0029","first-page":"13906","article-title":"Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway","volume-title":"Bioengineered","author":"Dai","year":"2022"},{"key":"2024110501461482600_CIT0030","first-page":"7904","article-title":"Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells","volume-title":"Bioengineered","author":"Zhang","year":"2022"},{"key":"2024110501461482600_CIT0031","first-page":"53","article-title":"Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells","volume-title":"Endocr Connect","author":"Hasenoehrl","year":"2017"},{"key":"2024110501461482600_CIT0032","first-page":"5684","article-title":"SK119, a novel shikonin derivative, leads to apoptosis in melanoma cell lines and exhibits synergistic effects with vemurafenib and cobimetinib","volume-title":"Int J Mol Sci","author":"Kretschmer","year":"2022"},{"key":"2024110501461482600_CIT0033","first-page":"102987","article-title":"The role of Shikonin in improving 5-aminolevulinic acid-based photodynamic therapy and chemotherapy on glioblastoma stem cells","volume-title":"Photodiagn Photodyn Ther","author":"Werner","year":"2022"},{"key":"2024110501461482600_CIT0034","first-page":"248","article-title":"Shikonin derivatives for cancer prevention and therapy","volume-title":"Cancer Lett","author":"Boulos","year":"2019"},{"key":"2024110501461482600_CIT0035","first-page":"1989","article-title":"Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine","volume-title":"Cancer Immunol Immunother","author":"Chen","year":"2012"},{"key":"2024110501461482600_CIT0036","first-page":"494","article-title":"Luminal breast cancer: from biology to treatment","volume-title":"Nat Rev Clin Oncol","author":"Ignatiadis","year":"2013"},{"key":"2024110501461482600_CIT0037","first-page":"2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume-title":"Nucleic Acids Res","author":"Klinge","year":"2001"},{"key":"2024110501461482600_CIT0038","first-page":"215","article-title":"The secrets of selective estrogen receptor modulation: cell-specific coregulation","volume-title":"Cancer Cell","author":"Jordan","year":"2002"},{"key":"2024110501461482600_CIT0039","first-page":"1371","article-title":"Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume-title":"J Natl Cancer Inst","author":"Fisher","year":"1998"},{"key":"2024110501461482600_CIT0040","first-page":"233","article-title":"A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells","volume-title":"Breast Cancer Res Treat","author":"Yao","year":"2010"},{"key":"2024110501461482600_CIT0041","first-page":"172667","article-title":"ER-mediated anti-tumor effects of shikonin on breast cancer","volume-title":"Eur J Pharmacol","author":"Yang","year":"2019"},{"key":"2024110501461482600_CIT0042","first-page":"33","article-title":"Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3\u03b2-regulated suppression of \u03b2-catenin signaling","volume-title":"Biochem Pharmacol","author":"Chen","year":"2019"},{"key":"2024110501461482600_CIT0043","first-page":"593","article-title":"Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators","volume-title":"Breast Cancer Res Treat","author":"Rhodes","year":"2014"},{"key":"2024110501461482600_CIT0044","first-page":"1601","article-title":"Shikonin as an inhibitor of the LPS-induced epithelial-to-mesenchymal transition in human breast cancer cells","volume-title":"Int J Mol Med","author":"Hong","year":"2015"},{"key":"2024110501461482600_CIT0045","first-page":"2672","article-title":"RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment","volume-title":"Sci Rep","author":"Lin","year":"2018"},{"key":"2024110501461482600_CIT0046","first-page":"47","article-title":"Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells","volume-title":"Cancer Lett","author":"Zhang","year":"2009"},{"key":"2024110501461482600_CIT0047","first-page":"52","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume-title":"Cell","author":"Kessenbrock","year":"2010"},{"key":"2024110501461482600_CIT0048","first-page":"1260","article-title":"Changing views of the role of matrix metalloproteinases in metastasis","volume-title":"J Natl Cancer Inst","author":"Chambers","year":"1997"},{"key":"2024110501461482600_CIT0049","first-page":"1756","article-title":"Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion","volume-title":"Mol Cancer Res","author":"Hu","year":"2009"},{"key":"2024110501461482600_CIT0050","first-page":"2827","article-title":"Shikonin blocks migration and invasion of human breast cancer cells through inhibition of matrix metalloproteinase-9 activation","volume-title":"Oncol Rep","author":"Jang","year":"2014"},{"key":"2024110501461482600_CIT0051","first-page":"777","article-title":"Shikonin inhibits the proliferation of human breast cancer cells by reducing tumor-derived exosomes","volume-title":"Molecules","author":"Wei","year":"2016"},{"key":"2024110501461482600_CIT0052","first-page":"1","article-title":"Biology of HER2 and its importance in breast cancer","volume-title":"Oncology (Huntingt)","author":"Yarden","year":"2001"},{"key":"2024110501461482600_CIT0053","first-page":"33","article-title":"HER2-targeted therapies\u2014a role beyond breast cancer","volume-title":"Nat Rev Clin Oncol","author":"Oh","year":"2020"},{"key":"2024110501461482600_CIT0054","first-page":"783","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume-title":"N Engl J Med","author":"Slamon","year":"2001"},{"key":"2024110501461482600_CIT0055","first-page":"233","article-title":"The epigenetics of triple-negative and basal-like breast cancer: current knowledge","volume-title":"J Breast Cancer","author":"Temian","year":"2018"},{"key":"2024110501461482600_CIT0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-018-0726-6","article-title":"Triple-negative breast cancers: systematic review of the literature on molecular and clinical features with a focus on treatment with innovative drugs","volume":"20","author":"Diana","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2024110501461482600_CIT0057","first-page":"27","article-title":"Progress in adjuvant systemic therapy for breast cancer","volume-title":"Nat Rev Clin Oncol","author":"Pond\u00e9","year":"2019"},{"key":"2024110501461482600_CIT0058","first-page":"463","article-title":"Shikonin is a novel and selective IMPDH2 inhibitor that target triple-negative breast cancer","volume-title":"Phytother Res","author":"Wang","year":"2021"},{"key":"2024110501461482600_CIT0059","first-page":"76","article-title":"Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p\/PTEN\/Akt pathway","volume-title":"J Cancer","author":"Bao","year":"2021"},{"key":"2024110501461482600_CIT0060","first-page":"105789","article-title":"In vitro characterization and molecular dynamic simulation of shikonin as a tubulin-targeted anticancer agent","volume-title":"Comput Biol Med","author":"Radha","year":"2022"},{"key":"2024110501461482600_CIT0061","first-page":"e2200742","article-title":"Inhibition of mitochondrial biosynthesis using a \u201cright-side-out\u201d membrane-camouflaged micelle to facilitate the therapeutic effects of shikonin on triple-negative breast cancer","volume-title":"Adv Healthc Mater","author":"Peng","year":"2022"},{"key":"2024110501461482600_CIT0062","first-page":"2020","article-title":"Shikonin induces an anti-tumor effect on murine mammary cancer via p38-dependent apoptosis","volume-title":"Oncol Rep","author":"Xu","year":"2019"},{"key":"2024110501461482600_CIT0063","first-page":"7261","article-title":"Shikonin induced necroptosis via reactive oxygen species in the T-47D breast cancer cell line","volume-title":"Asian Pac J Cancer Prev","author":"Shahsavari","year":"2015"},{"key":"2024110501461482600_CIT0064","first-page":"1459","article-title":"Mechanisms behind the inhibition of lung adenocarcinoma cell by shikonin","volume-title":"Cell Biochem Biophys","author":"Lan","year":"2014"},{"key":"2024110501461482600_CIT0065","first-page":"347","article-title":"The molecular machinery of regulated cell death","volume-title":"Cell Res","author":"Tang","year":"2019"},{"key":"2024110501461482600_CIT0066","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/cdd.2016.8","article-title":"Cancer therapy in the necroptosis era","volume":"23","author":"Su","year":"2016","journal-title":"Cell Death Differ"},{"key":"2024110501461482600_CIT0067","first-page":"455","article-title":"Necroptosis","volume-title":"N Engl J Med","author":"Linkermann","year":"2014"},{"key":"2024110501461482600_CIT0068","first-page":"1695","article-title":"Roles of RIPK3 in necroptosis, cell signaling, and disease","volume-title":"Exp Mol Med","author":"Morgan","year":"2022"},{"key":"2024110501461482600_CIT0069","first-page":"3165","article-title":"Pharmacological inhibition of necroptosis promotes human breast cancer cell proliferation and metastasis","volume-title":"Onco Targets Ther","author":"Shen","year":"2020"},{"key":"2024110501461482600_CIT0070","first-page":"265","article-title":"Shikonin induces necroptosis by reactive oxygen species activation in nasopharyngeal carcinoma cell line CNE-2Z","volume-title":"J Bioenerg Biomembr","author":"Zhang","year":"2017"},{"key":"2024110501461482600_CIT0071","first-page":"5507","article-title":"Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1\/RIP3 and synergizes the activity of gemcitabine","volume":"9","author":"Chen","year":"2017","journal-title":"Am J Transl Res"},{"key":"2024110501461482600_CIT0072","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-017-1223-7","article-title":"Shikonin-induced necroptosis is enhanced by the inhibition of autophagy in non-small cell lung cancer cells","volume":"15","author":"Kim","year":"2017","journal-title":"J Transl Med"},{"key":"2024110501461482600_CIT0073","first-page":"4479","article-title":"RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway","volume-title":"Tumour Biol","author":"Shahsavari","year":"2016"},{"key":"2024110501461482600_CIT0074","first-page":"245","article-title":"Targeting cell necroptosis and apoptosis induced by shikonin via receptor interacting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7","volume-title":"Anticancer Agents Med Chem","author":"Shahsavari","year":"2018"},{"key":"2024110501461482600_CIT0075","first-page":"36","article-title":"Shikonin induces programmed necrosis-like cell death through the formation of receptor interacting protein 1 and 3 complex","volume-title":"Food Chem Toxicol","author":"Park","year":"2013"},{"key":"2024110501461482600_CIT0076","first-page":"13","article-title":"Reactive oxygen species and mitochondrial dynamics: the yin and yang of mitochondrial dysfunction and cancer progression","volume-title":"Antioxidants (Basel, Switzerland)","author":"Je\u017eek","year":"2018"},{"key":"2024110501461482600_CIT0077","first-page":"1","article-title":"Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells","volume-title":"Evid Based Complement Alternat Med","author":"Wiench","year":"2013"},{"key":"2024110501461482600_CIT0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02780-y","article-title":"Induction of oxidative DNA damage, cell cycle arrest and p53 mediated apoptosis by calcium titanate nanoparticles in MCF-7 breast cancer cells","volume":"22","author":"Mohamed","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2024110501461482600_CIT0079","first-page":"e94180","article-title":"An oxidative stress mechanism of shikonin in human glioma cells","volume-title":"PLoS One","author":"Yang","year":"2014"},{"key":"2024110501461482600_CIT0080","first-page":"16","article-title":"Shikonin promotes ubiquitination and degradation of cIAP1\/2-mediated apoptosis and necrosis in triple negative breast cancer cells","volume-title":"Chin Med","author":"Wang","year":"2021"},{"key":"2024110501461482600_CIT0081","first-page":"1641","article-title":"Shikonin circumvents cancer drug resistance by induction of a necroptotic death","volume-title":"Mol Cancer Ther","author":"Han","year":"2007"},{"key":"2024110501461482600_CIT0082","first-page":"469","article-title":"Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses","volume-title":"Nat Rev Immunol","author":"Seong","year":"2004"},{"key":"2024110501461482600_CIT0083","first-page":"778","article-title":"Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance","volume-title":"Autophagy","author":"Lin","year":"2018"},{"key":"2024110501461482600_CIT0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0435-9","article-title":"Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components","volume":"14","author":"Lin","year":"2015","journal-title":"Mol Cancer"},{"key":"2024110501461482600_CIT0085","first-page":"43629","article-title":"Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1","volume-title":"Oncotarget","author":"Yin","year":"2016"},{"key":"2024110501461482600_CIT0086","first-page":"137414","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume-title":"Int J Breast Cancer","author":"Yardley","year":"2013"},{"key":"2024110501461482600_CIT0087","first-page":"153402","article-title":"Protection against chemotherapy-and radiotherapy-induced side effects: a review based on the mechanisms and therapeutic opportunities of phytochemicals","volume-title":"Phytomedicine","author":"Liu","year":"2021"},{"key":"2024110501461482600_CIT0088","first-page":"8629","article-title":"Cryptanshinone inhibits the glycolysis and inhibits cell migration through PKM2\/\u03b2-catenin axis in breast cancer","volume-title":"Onco Targets Ther","author":"Zhou","year":"2020"},{"key":"2024110501461482600_CIT0089","first-page":"2105","article-title":"Combination treatment using pyruvate kinase M2 inhibitors for the sensitization of high density triple-negative breast cancer cells","volume-title":"In Vivo","author":"Lee","year":"2022"},{"key":"2024110501461482600_CIT0090","first-page":"5986","article-title":"A compressive review about Taxol\u00ae: history and future challenges","volume-title":"Molecules","author":"Gallego-Jara","year":"2020"},{"key":"2024110501461482600_CIT0091","first-page":"e94079","article-title":"Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cells","volume-title":"PLoS One","author":"Li","year":"2014"},{"key":"2024110501461482600_CIT0092","first-page":"165","article-title":"Tamoxifen (\u2018Nolvadex\u2019): a review: antitumour treatment","volume-title":"Cancer Treat Rev","author":"Clemons","year":"2002"},{"key":"2024110501461482600_CIT0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13020-020-00305-1","article-title":"Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo","volume":"15","author":"Lin","year":"2020","journal-title":"Chin Med"},{"key":"2024110501461482600_CIT0094","first-page":"88658","article-title":"Shikonin reduces tamoxifen resistance through long non-coding RNA uc. 57","volume-title":"Oncotarget","author":"Zhang","year":"2017"},{"key":"2024110501461482600_CIT0095","first-page":"63","article-title":"Simultaneous quantitative analysis of shikonin and deoxyshikonin in rat plasma by rapid LC\u2013ESI\u2013MS\u2013MS","volume-title":"Chromatographia","author":"Huang","year":"2010"},{"key":"2024110501461482600_CIT0096","first-page":"355","article-title":"Determination of blood concentrations of main active compounds in Zi-Cao-Cheng-Qi decoction and their total plasma protein binding rates based on hollow fiber liquid phase microextraction coupled with high performance liquid chromatography","volume-title":"J Chromatogr B Analyt Technol Biomed Life Sci","author":"Li","year":"2018"},{"key":"2024110501461482600_CIT0097","first-page":"112105","article-title":"Synthesis and biological evaluation of novel shikonin-benzo [b] furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site","volume-title":"Eur J Med Chem","author":"Shao","year":"2020"},{"key":"2024110501461482600_CIT0098","first-page":"249","article-title":"Induction of phase I, II and III drug metabolism\/transport by xenobiotics","volume-title":"Arch Pharm Res","author":"Xu","year":"2005"},{"key":"2024110501461482600_CIT0099","first-page":"18","article-title":"Shikonin upregulates the expression of drug-metabolizing enzymes and drug transporters in primary rat hepatocytes","volume-title":"J Ethnopharmacol","author":"Huang","year":"2018"},{"key":"2024110501461482600_CIT0100","first-page":"117","article-title":"Shikonin, a constituent of Lithospermum erythrorhizon exhibits anti-allergic effects by suppressing orphan nuclear receptor Nr4a family gene expression as a new prototype of calcineurin inhibitors in mast cells","volume-title":"Chem Biol Interact","author":"Wang","year":"2014"},{"key":"2024110501461482600_CIT0101","first-page":"153805","article-title":"Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches","volume-title":"Phytomedicine","author":"Sun","year":"2022"},{"key":"2024110501461482600_CIT0102","first-page":"905755","article-title":"Review of shikonin and derivatives: isolation, chemistry, biosynthesis, pharmacology and toxicology","volume-title":"Front Pharmacol","author":"Yadav","year":"2022"},{"key":"2024110501461482600_CIT0103","first-page":"4019","article-title":"Successful in vivo hyperthermal therapy toward breast cancer by Chinese medicine shikonin-loaded thermosensitive micelle","volume-title":"Int J Nanomedicine","author":"Su","year":"2017"},{"key":"2024110501461482600_CIT0104","first-page":"103193","article-title":"Hyaluronic acid-coated shikonin liposomes for the treatment of triple-negative breast cancer via targeting tumor cells and amplification of oxidative stress","volume-title":"J Drug Delivery Sci Technol","author":"Meng","year":"2022"},{"key":"2024110501461482600_CIT0105","first-page":"204","article-title":"Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma","volume-title":"Int J Biol Macromol","author":"Li","year":"2018"},{"key":"2024110501461482600_CIT0106","first-page":"120310","article-title":"Hybrid micelles codelivering shikonin and IDO-1 siRNA enhance immunotherapy by remodeling immunosuppressive tumor microenvironment","volume-title":"Int J Pharm","author":"Li","year":"2021"},{"key":"2024110501461482600_CIT0107","first-page":"3684","article-title":"AS1411 aptamer\/hyaluronic acid-bifunctionalized microemulsion co-loading shikonin and docetaxel for enhanced antiglioma therapy","volume-title":"J Pharm Sci","author":"Wang","year":"2019"},{"key":"2024110501461482600_CIT0108","first-page":"9424","article-title":"Advanced drug delivery nanosystems for shikonin: a calorimetric and electron paramagnetic resonance study","volume-title":"Langmuir","author":"Kontogiannopoulos","year":"2018"},{"key":"2024110501461482600_CIT0109","first-page":"1361","article-title":"Sarcoma-targeting peptide-decorated polypeptide nanogel intracellularly delivers shikonin for upregulated osteosarcoma necroptosis and diminished pulmonary metastasis","volume-title":"Theranostics","author":"Li","year":"2018"},{"key":"2024110501461482600_CIT0110","first-page":"1195","article-title":"Promising nanomedicines of shikonin for cancer therapy","volume-title":"Int J Nanomedicine","author":"Yan","year":"2023"},{"key":"2024110501461482600_CIT0111","first-page":"129","article-title":"EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy","volume-title":"Adv Drug Deliv Rev","author":"Maeda","year":"2011"},{"key":"2024110501461482600_CIT0112","first-page":"1813","article-title":"RGD-targeted liposome binding and uptake on breast cancer cells is dependent on elastin linker secondary structure","volume-title":"Bioconjug Chem","author":"Veneti","year":"2016"},{"key":"2024110501461482600_CIT0113","first-page":"81","article-title":"RGD-peptide conjugated inulin-ibuprofen nanoparticles for targeted delivery of Epirubicin","volume-title":"Colloids Surf B","author":"Zhang","year":"2016"},{"key":"2024110501461482600_CIT0114","first-page":"268","article-title":"Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells","volume-title":"Molecules","author":"Wen","year":"2018"},{"key":"2024110501461482600_CIT0115","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.3390\/molecules28186725","article-title":"Shikonin causes an apoptotic effect on human kidney cancer cells through Ras\/MAPK and PI3K\/AKT pathways","volume":"28","author":"Kir\u00e1ly","year":"2023","journal-title":"Molecules"},{"key":"2024110501461482600_CIT0116","doi-asserted-by":"crossref","first-page":"e040923220678","DOI":"10.2174\/1874467217666230904104414","article-title":"Research progress of the molecular mechanism of antithyroid cancer activity of shikonin","volume":"17","author":"Sun","year":"2024","journal-title":"Curr Mol Pharmacol"},{"key":"2024110501461482600_CIT0117","first-page":"2981","article-title":"Natural products for the prevention, treatment and progression of breast cancer","volume-title":"Cancers","author":"Svolacchia","year":"2023"},{"key":"2024110501461482600_CIT0118","first-page":"3012","article-title":"Impact of natural products on developing new anti-cancer agents","volume-title":"Chem Rev","author":"Cragg","year":"2009"},{"key":"2024110501461482600_CIT0119","first-page":"52","article-title":"Drug development from natural resource: a systematic approach","volume-title":"Mini Rev Med Chem","author":"Sharma","year":"2015"},{"key":"2024110501461482600_CIT0120","first-page":"916","article-title":"Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NF\u03baB, cyclinD and MMP-1 transcription","volume-title":"Phytomedicine","author":"Liu","year":"2009"},{"key":"2024110501461482600_CIT0121","first-page":"223","article-title":"Induction of apoptosis and inhibition of c-erb B-2 in breast cancer cells by flavopiridol","volume":"6","author":"Li","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2024110501461482600_CIT0122","first-page":"905","article-title":"Enterolactone suppresses proliferation, migration and metastasis of MDA-MB-231 breast cancer cells through inhibition of uPA induced plasmin activation and MMPs-mediated ECM remodeling","volume-title":"Asian Pac J Cancer Prev","author":"Mali","year":"2017"},{"key":"2024110501461482600_CIT0123","first-page":"337","article-title":"Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cells","volume-title":"Expert Opin Ther Targets","author":"Wang","year":"2013"},{"key":"2024110501461482600_CIT0124","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcp.24780","article-title":"Thymoquinone restores radiation-induced TGF-\u03b2 expression and abrogates EMT in chemoradiotherapy of breast cancer cells","volume":"230","author":"Rajput","year":"2015","journal-title":"J Cell Physiol"},{"key":"2024110501461482600_CIT0125","first-page":"00075","article-title":"Hypericin-based photodynamic therapy induces a tumor-specific immune response and an effective DC-based cancer immunotherapy","volume":"S0006-2952","author":"Zheng","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"2024110501461482600_CIT0126","first-page":"598","article-title":"Clinical trial on the effects of shikonin mixture on later stage lung cancer","volume":"11","author":"Guo","year":"1991","journal-title":"Zhong xi yi jie he za zhi= Chin J Mod Develop Tradit Med"},{"key":"2024110501461482600_CIT0127","first-page":"178","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume-title":"Nat Rev Mol Cell Biol","author":"Lamouille","year":"2014"},{"key":"2024110501461482600_CIT0128","first-page":"949","article-title":"PI3K-AKT-mTOR and NF\u03baB pathways in ovarian cancer: implications for targeted therapeutics","volume-title":"Cancers","author":"Ghoneum","year":"2019"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/8\/967\/60416446\/rgae041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/76\/8\/967\/60416446\/rgae041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T01:46:47Z","timestamp":1730771207000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/76\/8\/967\/7656703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":128,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgae041","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8,1]]}}}